Progyny, Inc. (NASDAQ:PGNY) Shares Bought by RiverPark Advisors LLC

RiverPark Advisors LLC boosted its holdings in Progyny, Inc. (NASDAQ:PGNY) by 362.4% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,934 shares of the company’s stock after purchasing an additional 3,867 shares during the quarter. RiverPark Advisors LLC’s holdings in Progyny were worth $188,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. TFC Financial Management Inc. acquired a new position in Progyny in the first quarter valued at $42,000. Financial Management Professionals Inc. acquired a new position in Progyny in the first quarter valued at $52,000. Parkside Financial Bank & Trust increased its stake in Progyny by 9.3% in the fourth quarter. Parkside Financial Bank & Trust now owns 3,096 shares of the company’s stock valued at $115,000 after purchasing an additional 264 shares during the last quarter. Assetmark Inc. increased its stake in Progyny by 26.8% in the fourth quarter. Assetmark Inc. now owns 3,756 shares of the company’s stock valued at $140,000 after purchasing an additional 793 shares during the last quarter. Finally, Cetera Trust Company N.A acquired a new position in Progyny in the fourth quarter valued at $183,000. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently commented on PGNY. Cantor Fitzgerald reiterated an “overweight” rating and issued a $48.00 target price on shares of Progyny in a research note on Thursday, May 16th. Canaccord Genuity Group lowered their price target on Progyny from $46.00 to $37.00 and set a “buy” rating for the company in a research report on Friday, May 10th. Barclays lowered their price target on Progyny from $48.00 to $30.00 and set an “overweight” rating for the company in a research report on Monday, May 13th. BTIG Research lowered their price target on Progyny from $50.00 to $41.00 and set a “buy” rating for the company in a research report on Friday, May 10th. Finally, Truist Financial lowered their price target on Progyny from $46.00 to $37.00 and set a “buy” rating for the company in a research report on Friday, May 17th. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $43.11.

Insider Transactions at Progyny

In related news, President Michael E. Sturmer sold 4,515 shares of the stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $31.95, for a total value of $144,254.25. Following the completion of the transaction, the president now owns 380,038 shares of the company’s stock, valued at $12,142,214.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Cheryl Scott sold 1,462 shares of the stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $28.39, for a total value of $41,506.18. Following the completion of the transaction, the director now owns 10,098 shares of the company’s stock, valued at $286,682.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, President Michael E. Sturmer sold 4,515 shares of the stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $31.95, for a total value of $144,254.25. Following the completion of the transaction, the president now directly owns 380,038 shares of the company’s stock, valued at approximately $12,142,214.10. The disclosure for this sale can be found here. Company insiders own 12.30% of the company’s stock.

Progyny Stock Down 0.3 %

Shares of NASDAQ PGNY traded down $0.09 on Tuesday, hitting $28.16. The company had a trading volume of 716,483 shares, compared to its average volume of 965,733. Progyny, Inc. has a 12-month low of $23.90 and a 12-month high of $44.95. The business has a 50 day moving average of $28.03 and a two-hundred day moving average of $33.79. The firm has a market capitalization of $2.68 billion, a P/E ratio of 46.16, a PEG ratio of 1.84 and a beta of 1.46.

Progyny (NASDAQ:PGNY) last issued its earnings results on Thursday, May 9th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.03. Progyny had a return on equity of 11.61% and a net margin of 5.53%. The company had revenue of $278.08 million during the quarter, compared to the consensus estimate of $289.41 million. During the same quarter in the prior year, the business earned $0.18 earnings per share. The company’s revenue was up 7.6% compared to the same quarter last year. On average, sell-side analysts anticipate that Progyny, Inc. will post 0.73 earnings per share for the current year.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.